Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | CMA1 | P23946 | 1/20 | 0.57 |
| ▸ | TACR1 | P25103 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.54 |
| ▸ | CLPP | Q16740 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8112987 | 0.91 | SIGMAR1 (0.70) | SIGMAR1KMT2AKDM4EALDH1A1CMA1 | |
| SCHEMBL667100 | 0.91 | SIGMAR1 (0.70) | SIGMAR1KMT2AKDM4EALDH1A1CMA1 | |
| SCHEMBL9830068 | 0.85 | KMT2A (0.49) | SIGMAR1KMT2AKDM4ETACR1MEN1 | |
| SCHEMBL9829472 | 0.82 | ABCB1 (0.57) | SIGMAR1KDM4ECMA1TACR1DRD4 | |
| SCHEMBL20804357 | 0.81 | SIGMAR1 (0.90) | SIGMAR1KMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL28186295 | 0.81 | SIGMAR1 (0.90) | SIGMAR1KMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL9829721 | 0.81 | MEN1 (0.54) | KMT2AKDM4EALDH1A1MEN1CLPP | |
| SCHEMBL29234312 | 0.80 | SIGMAR1 (0.58) | SIGMAR1KMT2AKDM4EALDH1A1CMA1 | |
| SCHEMBL30945865 | 0.80 | SIGMAR1 (0.58) | SIGMAR1KMT2AKDM4EALDH1A1CMA1 | |
| SCHEMBL30774908 | 0.79 | SIGMAR1 (0.79) | SIGMAR1KMT2AKDM4EALDH1A1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0449989-A1 | 6,7 DIHYDROPYRROLO 3,4-c] PYRIDO 2,3-d] PYRIMIDINE DERIVATIVES | Sloan-Kettering Institute For Cancer Research (US) | 1991-10-09 | — | — | EP | claimed |
| WO-1990007496-A1 | 6,7 DIHYDROPYRROLO[3,4-c] PYRIDO[2,3-d] PYRIMIDINE DERIVATIVES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1990-07-12 | — | — | WO | claimed |
| US-9045468-B2 | 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| EP-2606049-A2 | 2,5-METHANO-AND 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | Albany Molecular Research, Inc. (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20120046271-A1 | 2,5-Methano- and 2,5-Ethano-Tetrahydrobenzazepine Derivatives And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine, and Serotonin | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2012024397-A2 | 2,5-METHANO-AND 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| EP-0449989-A1 | 6,7 DIHYDROPYRROLO 3,4-c] PYRIDO 2,3-d] PYRIMIDINE DERIVATIVES | Sloan-Kettering Institute For Cancer Research (US) | 1991-10-09 | — | — | EP | disclosed |
| WO-1990007496-A1 | 6,7 DIHYDROPYRROLO[3,4-c] PYRIDO[2,3-d] PYRIMIDINE DERIVATIVES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1990-07-12 | — | — | WO | disclosed |
| US-4925939-A | 6,7-dihydropyrrol[3,4-c]pyrido[2,3-d]pyrimidine derivatives | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1990-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046271-A1 | 2,5-Methano- and 2,5-Ethano-Tetrahydrobenzazepine Derivatives And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine, and Serotonin | HTR2B, HTR1B, HTR5A | SIGMAR1 97/4885KMT2A 2571/4885KDM4E 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.